California State Teachers Retirement System Increases Stake in Sangamo Therapeutics Inc (NASDAQ:SGMO)

California State Teachers Retirement System lifted its holdings in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 5.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 132,741 shares of the biopharmaceutical company’s stock after buying an additional 6,360 shares during the quarter. California State Teachers Retirement System owned about 0.16% of Sangamo Therapeutics worth $1,991,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SGMO. Russell Investments Group Ltd. acquired a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth approximately $203,000. Schwab Charles Investment Management Inc. grew its position in shares of Sangamo Therapeutics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock worth $2,353,000 after buying an additional 1,558 shares during the period. Bank of New York Mellon Corp grew its position in shares of Sangamo Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 339,842 shares of the biopharmaceutical company’s stock worth $2,990,000 after buying an additional 6,537 shares during the period. Principal Financial Group Inc. grew its position in shares of Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 832 shares during the period. Finally, Swiss National Bank grew its position in shares of Sangamo Therapeutics by 26.4% during the 2nd quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 30,000 shares during the period. Institutional investors own 64.06% of the company’s stock.

Several equities research analysts have recently commented on the stock. BidaskClub cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Jefferies Group restated a “buy” rating and set a $18.00 price objective on shares of Sangamo Therapeutics in a report on Friday, October 13th. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Wedbush restated a “hold” rating and set a $6.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Finally, Piper Jaffray Companies set a $25.00 price objective on shares of Sangamo Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Sangamo Therapeutics currently has an average rating of “Buy” and an average price target of $18.83.

In other news, Director Steven J. Mento sold 11,520 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $20.59, for a total value of $237,196.80. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $102,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $18.49, for a total transaction of $92,450.00. The disclosure for this sale can be found here. Insiders sold 89,953 shares of company stock valued at $1,618,193 in the last quarter. Corporate insiders own 5.50% of the company’s stock.

Shares of Sangamo Therapeutics Inc (SGMO) traded down $0.40 during midday trading on Friday, reaching $19.60. 2,701,044 shares of the company were exchanged, compared to its average volume of 1,689,241. The firm has a market capitalization of $1,630.00, a PE ratio of -28.41 and a beta of 2.87. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. Sangamo Therapeutics Inc has a 52-week low of $3.60 and a 52-week high of $22.85.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The business’s revenue for the quarter was up 333.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.27) earnings per share. analysts forecast that Sangamo Therapeutics Inc will post -0.73 EPS for the current year.

WARNING: “California State Teachers Retirement System Increases Stake in Sangamo Therapeutics Inc (NASDAQ:SGMO)” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://ledgergazette.com/2018/02/10/california-state-teachers-retirement-system-has-1-99-million-holdings-in-sangamo-therapeutics-inc-sgmo.html.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply